Risk Minimisation Materials

Kadcyla (trastuzumab emtansine) EU Healthcare Professional Information - prevention of medication errors

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan. Please register or log in to view the materials.

For Healthcare Professionals

A GUIDE FOR HEALTHCARE PROFESSIONALS

Important Safety Information: Please read this guide carefully and use it when prescribing KANUMA® as it contains essential safety and efficacy information. The guide was created as part of the KANUMA® Risk Management Plan and includes risk-minimising measures for the safe and effective use of this medicinal product. The guide is a mandatory part of the approval process for KANUMA®, to help ensure that healthcare professionals take into account the special safety requirements of prescribing this medicinal product.

For Healthcare Professionals

DHCP Keppra Oral solution

Dear Healthcare Professional Communication related to risk of medication errors associated with overdose for Keppra Oral solution.

For Healthcare Professionals

Checklist for the prescriber

Checklist for the prescriber: Minimising the risk of photosensitivity with topical ketoprofen

For Healthcare Professionals

Information sheet for patients

Information sheet for patients: Minimising the risk of skin reactions with topical ketoprofen

Kevzara - Healthcare professional (HCP) – Education / Discussion Guide - Risk Minimisation Information for Healthcare Professionals

For hard copies please contact our medical information department at 08453727101 or email [email protected]

For Healthcare Professionals

Kevzara (sarilumab)- Patient Alert card-Risk Minimisation Information for Patients

This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with KEVZARA For hard copies please contact our medical information department at 0845 372 7101 or email [email protected] .

Keytruda (Pembrolizumab): Patient Alert Card

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with pembrolizumab

Keytruda (pembrolizumab): Important safety information to minimise the risk of immune-related adverse reactions: Heathcare Professional Frequently Asked Questions

As part of the terms of the Marketing Authorisation for Keytruda, MSD are required to ensure that all Healthcare Professionals who are likely to treat patients with pembrolizumab are provided with risk minimisation materials This document contains key information to help minimize the risk of immune-mediated side-effects such as immune-related pneumonitis, colitis, hepatitis, nephritis, endocrinopathies (including hypophysitis, type 1 diabetes mellitus,(including diabetic ketoacidosis, hypothyroidism, hyperthyroidism, and thyroiditis)) and other immune-related adverse reactions, providing guidance on how to monitor and manage them. It also draws attention to the availability of the Patient Information Brochure and Patient Alert Card. If you require further information about pembrolizumab and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information services on 01992 467272.

For Healthcare Professionals

Keytruda (pembrolizumab): Information for Patients Brochure: Important safety information to minimise the risk of immune-related adverse reactions

As part of the terms of the Marketing Authorisation for Keytruda, MSD are required to provide patients with information to help minimise the risk of immune-related adverse reactions that may occur with treatment with pembrolizumab. Please ensure that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with pembrolizumab.

Keytruda- explanatory note to RMM

Updated RMM were distributed to the agreed list of HCPs on 18 Sept 17. This update consolidates the following new information: -PRAC recommendation on solid organ transplant rejection. -Update to add a warning for the risk of severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. -Addition of the adverse event of myocarditis. -Addition of a new indication for monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy or who are not eligible for cisplatin-containing chemotherapy.

Kineret Patient Booklet

The material above is available for Kineret when used in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).

Using Kineret. A Guide for Healthcare Professionals

The material above is available for Kineret when used in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).

For Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Kyleena Differentiation Booklet

Kyleena Education Pack - Differentiation of Mirena, Jaydess and Kyleena.

For Healthcare Professionals